Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of procalcitonin (PCT) in risk stratification and prognosis of patients with a primary, non-infectious disease

Use of procalcitonin (PCT) in risk stratification and prognosis of patients with a primary, non-infectious disease

US Patent 11241395 · Granted Feb 8, 2022

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Method for diagnosing or monitoring kidney function or diagnosing kidney dysfunc2025
Anti-adrenomedullin antibodies and pharmaceutical compositions thereof2025
Adrenomedullin assays and methods for determining mature andrendomedullin2025
Adrenomedullin assays and methods for determining mature andrendomedullin2025
Hetero-halo inhibitors of histone deacetylase2024
Selenoprotein P for prediction of a first cardiovascular event2023
Procalcitonin for the prognosis of adverse events2023
Methods for determining DPP3 and therapeutic methods2023
Adrenomedullin assays and methods for determining mature adrenomedullin2023
Method of modulating the adrenomedullin (ADM) activity of a patient by administe2023
Method for predicting the risk of incidence of chronic kidney disease2023
DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the2022